TCG Crossover

TCGX provides patient capital to advance innovative drug discovery companies by investing in both pre-IPO and public biopharma firms. The firm operates as a Palo Alto–based registered investment adviser and deploys capital from closed-end funds into companies developing medicines driven by recent scientific breakthroughs. TCGX supports portfolio companies with a network of scientific advisors and operational executives, including Nobel and Lasker awardees, to guide drug development strategy. It focuses on opportunities in North America, Europe, and China and positions itself as a long-term partner for visionary founders and management teams.